Having trouble accessing articles? Reset your cache.

Ablavar gadofosveset regulatory update

FDA said it will contraindicate 3 gadolinium-based MRI contrast agents in patients with acute kidney injury or chronic severe kidney disease: Magnevist

Read the full 222 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE